Valneva today announced that it has completed recruitment for the pivotal Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
The Company also initiated an antibody persistence trial to follow the immunogenicity of a subset of participants for a period of five years.
The website uses cookies to ensure you get the best experience on our website.
Anonymous evaluation for troubleshooting and further development
Purpose: error analysis, statistical evaluation of our website accesses, campaign analysis, conversion tracking, retargeting
Processing operations: Collection of access data, data from your browser and data about the content accessed; Execution of analysis software and storage of data on your terminal device, anonymization of the data collected; Evaluation of the anonymous data in the form of statistics
Storage period: data on your device for up to two years.
Joint controller: Google Ireland Limited, Gordon House, Barrow Street, Dublin 4, Ireland Legal basis for data processing: voluntary, consent that can be revoked at any time Consequences of non-consent: No direct impact on the functionality of the website; however limited opportunities for further development and error analysis
Data transfer to the USA: Your data is processed by the provider Google in the USA, which involves corresponding risks, e.g. B. a secret data access by US authorities. With your consent, you also consent to the processing of your data in the USA.
